

Celltrion Healthcare Discuss Biosimilar Drug Approval and Look Ahead into the Patent Expiry of Top Selling Biologics

SMi Reports: Celltrion Healthcare Present Proven Case Study Insight at 8th Annual Biosimilars Industry Summit

LONDON, ENGLAND, UNITED KINGDOM, June 27, 2017

/EINPresswire.com/ -- SMi Group are delighted to welcome the expertise of Celltrion Healthcare when they present a keynote address at the 8th annual industry summit on [Biosimilars & Biobetters](#) this September.

Highlights from the talk presented by HoUng Kim, Division Head for Strategy and Operations include:

The Challenges of Gaining Approval: Attendees will leverage stringent standard criteria to overcome challenges in regulation as Celltrion draw from experience on the successful approval of two biosimilar drugs.



Great diversity of presenters and topics - very enjoyable"
Pfizer - Past Attendee

Publishing Data: The presentation will cover ARD requirement on sensitivity analysis and discuss ways in which Celltrion demonstrated a similar response rate regardless of different statistical approaches.


Future Landscape of Biosimilars: The talk will look ahead into the tremendous expansion expected in biosimilars surrounding the patent expiry of top selling biologics in coming years. Progressive outlook will also be given on the industry shift towards personalised and convenient treatments.

Other [speakers on the panel for 2017](#) will include Boehringer Ingelheim; Norwegian Medicines Agency; QuintilesIMS; Gedeon Richter; Teva Pharmaceuticals; Biocon; Prolong Pharmaceuticals; Merck Group and Lupin Europe.

Further details are available online at www.biosimilars-europe.com

Biosimilars & Biobetters
27th & 28th September 2017
Holiday Inn Kensington Forum, London UK

--end --



The banner features the SMi and Celltrion logos at the top left. Text on the right states: "SMi Group is proud to have Celltrion Healthcare present a keynote at Biosimilars 2017" and "Holiday Inn Kensington Forum, London UK www.biosimilars-europe.com". A central section introduces "HOUNG KIM, Division Head Strategy and Operations, Celltrion Healthcare" with a small portrait. Below this, it says "Case study insight on evidence based approaches" and lists three bullet points: "Challenges gaining approval", "Publishing data on clinical studies", and "Future landscape of biosimilars". The bottom right of the banner shows two red capsules and a date box for "27 - 28 SEPT 2017".

Celltrion Healthcare at Biosimilars 2017

Contact Information:

For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
2078276000
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.



SMi's 8th annual event...

Biosimilars & Biobetters

Holiday Inn Kensington Forum,
London UK

27 - 28
SEPT
2017

www.biosimilars-europe.com

Biosimilars & Biobetters 2017

The poster features a blue background with a close-up image of red and white capsules. A pink square with white text indicates the dates '27 - 28 SEPT 2017'. The website 'www.biosimilars-europe.com' is listed at the bottom of the poster area.